Stefan Mauss

Stefan Mauss

Auto-generated profile, based on publicly available information

Stefan Mauss

Center for HIV and Hepatogastroenterology Düsseldorf Germany

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Journal of Hepatology
Verified
Journal Article
Closed access
SMStefan Mauss
Stefan Mauss
FBFlorian Berger
Florian Berger
NFNatalie Filmann
Natalie Filmann
DHDietrich Hueppe
Dietrich Hueppe
JHJulia Henke
Julia Henke
EHEva Herrmann
Eva Herrmann

28 June 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
SMStefan Mauss
Stefan Mauss
DHDietrich Hueppe
Dietrich Hueppe
UAUlrich Alshuth
Ulrich Alshuth
In clinical trials with telaprevir (TLV) and boceprevir (BOC) renal impairment was not reported as a relevant adverse event. The PAN study is a noninterventional study enrolling patients treated with peginterferon alfa-2a/ribavirin (PEG/RBV) with or without TVL or BOC. Here we restrict the analysis to hepatitis C virus genotype 1 patients having completed 12 (n = 895) or 24 weeks (n = 591) of treatment. For estimation of glomerular filtration rate (eGFR) the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was chosen. Patients on TLV 38/575 (6.6%) and BOC 10/211 (4.7%) more frequently experienced a decrease in eGFR to <60 mL/min compared to patients on PEG/RBV 1/109 (0.9%) (P < 0.05). Risk factors associated with eGFR <60 mL/min in multiple logistic regression analysis were age (P < 0.001), arterial hypertension (P < 0.05), higher serum creatinine at baseline (P < 0.001), and being on triple therapy with TLV or BOC (P < 0.01). Patients with an eGFR of 60 mL/min (9.7 g/dL ± 1.4 g/dL versus 11.0 g/dL ± 1.7 g/dL) (P < 0.001). Most patients on TLV with a decrease of eGFR <60 mL/min showed a marked improvement in renal function after discontinuation of TLV. Conclusion: Renal impairment has not been reported as a safety signal in clinical trials with TVL or BOC. However, in this large cohort including patients with risk factors for renal impairment a marked decline in renal function was observed in about 5% of patients on triple therapy. In addition to being a safety concern, substantial ribavirin dose reductions have to be considered in these patients, as anemia was more pronounced in patients with impaired renal function. (Hepatology 2014;58:46–48)

1 November 2008 in Antiviral Therapy
Verified
Journal Article
Closed access
SMStefan Mauss
Stefan Mauss
FBFlorian Berger
Florian Berger
DKDieter Kuschak
Dieter Kuschak
JHJulia Henke
Julia Henke
PHPetra Hegener
Petra Hegener
GSGuenther Schmutz
Guenther Schmutz
Background: Broad use of tenofovir and an ageing HIV-infected population have created an interest in renal function in HIV patients. Serum cystatin C is a newer marker of renal function and might be more sensitive than creatinine. Methods: Patients were enrolled consecutively in an observational study. HIV-seropositive patients naive to antiretroviral therapy ( n=261) were compared with healthy volunteers undergoing check-up procedures ( n=193). Estimated glomerular filtration rate (eGFR) was derived using creatinine-based Modification of Diet in Renal Disease (MDRD) and Cockcroft–Gault formulas or cystatin C-based calculations. HIV-seropositive patients starting antiretroviral therapy ( n=92) were followed prospectively after enrolment. Results: MDRD showed a higher median eGFR in antiretroviral- naive HIV-seropositive patients compared with controls (104 versus 93 ml/min; P<0.001). Cockcroft–Gault gave similar results (118 versus 106 ml/min; P<0.001). By contrast, cystatin C levels in HIV-seropositive individuals were higher, resulting in a lower median eGFR compared with controls (99 versus 120 ml/min; P<0.001). Cystatin C was positively correlated with HIV RNA ( r=0.33, P<0.01) and inversely correlated with CD4 + T-cell count ( r=-0.29, P<0.01). Initiating antiretroviral therapy ( n=92) decreased cystatin C levels and led to an increased cystatin C-based eGFR from median 84 to 103 ml/min at week 24 ( P<0.001). Serum creatinine was not substantially altered. Conclusions: Correlation of cystatin C with HIV RNA and CD4 + T–cell count, plus decrease of cystatin C after suppression of HIV replication, suggest an increase of cystatin C levels by active HIV infection. This might result in overestimation of renal impairment, particularly in treatment-naive patients. Therefore, use of cystatin C to calculate GFR in HIV-seropositive individuals should not be recommended without further validation.

1 January 2017 in Antiviral Therapy
Verified
Journal Article
Closed access
SMStefan Mauss
Stefan Mauss
FBFlorian Berger
Florian Berger
MWMalte H Wehmeyer
Malte H Wehmeyer
PIPatrick Ingiliz
Patrick Ingiliz
DHDietrich Hueppe
Dietrich Hueppe
SCStefan Christensen
Stefan Christensen
Background: HCV has complex interactions with human lipid metabolism leading to down regulation of cholesterol levels. Interferon (IFN) therapy has been shown to decrease cholesterol even further. With the availability of second-generation direct-acting antiviral agents (DAA) the effect of suppressing and eliminating HCV on lipid metabolism warrants reevaluation. Methods: Prospective German multicentre cohort on HCV- and HIV–HCV-infected patients treated with direct-antiviral agents (GECCO). Lipids were assessed at baseline, during and after therapy. Wilcoxon test corrected for multiple testing was used. Results: For the analysis, 520 patients with chronic hepatitis C were available. Patients with chronic hepatitis C were treated as follows: sofosbuvir (SOF)/pegylated IFN (PEG-IFN)/ribavirin (RBV; HCV=34, HIV–HCV=36), SOF/ RBV (HCV=47, HIV–HCV=16), SOF/simeprevir (HCV=9, HCV–HIV=2), SOF/daclatasvir +/- RBV (HCV=27, HIV–HCV=47), SOF/ledipasvir +/- RBV (HCV=147, HCV–HIV=100) and ombitasvir/paritaprevir/ritonavir +/-dasabuvir +/- RBV (2D, HCV=2, HCV–HIV=6; 3D, HCV=39, HCV–HIV=8). On treatment there was a statistically significant increase in total cholesterol for any IFN-free DAA regimen, which was maintained after end of therapy. Changes of total cholesterol were driven by changes in low-density lipoprotein cholesterol, whereas high-density lipoprotein cholesterol remained unchanged. In contrast, total cholesterol decreased on SOF/PEG-IFN/RBV and increased after end of therapy above baseline levels. Triglycerides increased during treatment with SOF/PEG-IFN/RBV, but not on DAA-only regimens. Conclusions: Suppressing and eliminating HCV with IFN-free DAA regimens increased cholesterol levels, but had no effect on triglycerides. In contrast IFN-based therapy decreased cholesterol and increased triglycerides during treatment and led to increases in cholesterol after achieving sustained virological response.

26 June 2019 in Liver International
Verified
Journal Article
Closed access
PDF file
Frank TackeFrank Tacke
Frank Tacke
KBKlaus H.W. Boeker
Klaus H.W. Boeker
HKHartwig Klinker
Hartwig Klinker
RHRenate Heyne
Renate Heyne
PBPeter Buggisch
Peter Buggisch
SMStefan Mauss
Stefan Mauss

1 March 2018 in United European Gastroenterology Journal
Verified
Journal Article
Open access
CSChristoph Höner zu Siederdissen
Christoph Höner zu Siederdissen
PBPeter Buggisch
Peter Buggisch
KBKlaus Böker
Klaus Böker
ESEckart Schott
Eckart Schott
HKHartwig Klinker
Hartwig Klinker
SMStefan Mauss
Stefan Mauss
Background: In pivotal studies with direct‐acting antivirals (DAAs), rates of sustained virological response in hepatitis C genotype 1 infection are >90%.Objective: The objective of this article is to assess real‐world safety and effectiveness of DAA treatment in a prospective multicenter registry study.Methods: The German Hepatitis C‐Registry includes 6606 patients with genotype 1 from 246 centers, treated between February 2014 and June 2016 at the discretion of the physician.Results: A total of 4846 patients completed treatment and follow‐up; 51% of these patients were treatment experienced and 28% had liver cirrhosis. Comorbidities were reported in 76% of patients, including HIV co‐infection in 8%. SVR12 was 92% with 91% in GT1a and 93% in GT1b. HIV co‐infected patients (n = 247) had an SVR12 of 92%. Treatment was discontinued prematurely in 2.5%. In multivariate analysis, SVR12 was dependent on the choice of antiviral regimen (OR 1.33 (1.24–1.43); p < 0.001), negatively associated with presence of liver cirrhosis (OR 0.71 (0.56–0.89); p < 0.003) and positively associated with female gender (OR 1.52 (1.21–1.91); p < 0.001).Conclusion: Data from this real‐world registry show SVR12 rates close to those obtained in clinical studies. Discontinuation rates are low, confirming good tolerance of the regimens and good adherence of patients (Trial registration number DRKS00009717, German Clinical Trials Register, DRKS).